Merck & Co. in Cancer Pact
By

By
Merck & Co. has formed a clinical research collaboration with Genexine, a Pangyo Techno Valley, Korea-based clinical-stage biotechnology company, to assess Genexine’s GX-188E, a human papillomavirus (HPV)-therapeutic DNA vaccine, in…

AbbVie, Halozyme End Development Program
By

By
AbbVie has discontinued a development program with Halozyme Therapeutics, a San Diego-headquartered biotechnology company, using the Halozyme Enhanze platform technology, a drug-delivery platform, and a tumor necrosis factor alpha (TNF-alpha)…

Grünenthal Boosts Pain Drug Portfolio
By

By
Grünenthal, an Aachen, Germany-headquartered research-based pharmaceutical company, has acquired Thar Pharmaceuticals, a Pittsburgh, Pennsylvania-based clinical-stage specialty pharmaceutical company, to expand its development portfolio for treating complex regional pain syndrome (CRPS).…

Pfizer Names New Head of Global Supply
By

By
Pfizer has announced that Anthony J. Maddaluna, executive vice president (EVP) and president of Pfizer Global Supply will retire from the company after more than 41 years with Pfizer. Mr.…

Lilly Nixes Regulatory Submission of Alzheimer’s Drug
By

By
Eli Lilly and Company has said it will not pursue regulatory submissions for its biologic drug candidate, solanezumab, for treating mild dementia due to Alzheimer’s disease, following disappointing results of…

Shire Establishes Rare Disease Innovation Hub
By

By
Shire has announced that it will establish a rare disease innovation hub at its site in Cambridge, Massachusetts and has leased a 343,000-square-foot building in the Kendall Square location for…

Hikma in Pact for Generic Respiratory Drug
By

By
Hikma Pharmaceuticals, an Amman, Jordan-headquartered pharmaceutical company, has signed a development and licensing agreement with Vectura, a Chippenham, UK-headquartered pharmaceutical company, for its generic respiratory-drug product, VR730 (salmeterol), a long…

Allergan Buys Chase in $125-Million Deal
By

By
Allergan has acquired Chase Pharmaceuticals, an Irvine, California-headquartered clinical-stage biopharmaceutical company focused on neurodegenerative disorders, for an upfront payment of $125 million (subject to certain adjustments) and additional potential regulatory…

J&J in Talks for Potential Swiss Firm Acquisition
By

By
Johnson & Johnson (J&J) has confirmed that is engaged in preliminary discussions with Actelion Pharmaceuticals, an Allschwil, Basel, Switzerland-headquartered biopharmaceutical company, regarding a potential transaction. Acetlion also confirmed that it…

Roche Sells US API Manufacturing Facility to Patheon
By

By
Roche has signed a definitive agreement with Patheon under which Patheon will acquire Roche’s active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina. Under the agreement, Patheon will acquire…